Methods of intravenous administration of glyburide

Inventors

Jacobson, Sven Martin

Assignees

Remedy Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10052280-B2

Patent

Publication Date

2018-08-21

Expiration Date


Abstract

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Core Innovation

The patent describes treating a sulfonylurea-responsive condition in a patient by administering a glyburide drug in a clinically-effective manner. The administration includes a first dose during a first period of time, a second dose during a second period of time, and a third dose during a third period of time, with the second dose delivering less glyburide per unit of time than the first dose and the third dose delivering less glyburide per unit of time than the second dose.

The dosing regimen is directed to achieving a clinically-effective level and, in one embodiment, a substantially steady-state level of a glyburide drug. The regimen uses decreased per-unit-time delivery across three time-separated periods, including intravenous administration concepts with a bolus followed by a continuous infusion for greater than 20 hours and extended multi-hour regimens.

The patent describes example multi-phase dosing that includes a bolus and then a first infusion period followed by a second infusion period, for a total dosing period of about 72 hours. It also describes target low dose ranges per day and reports Phase 1 pharmacokinetic and pharmacodynamic findings from bolus plus a continuous infusion over approximately three days.

Claims Coverage

The provided independent claims are clm-00001 and clm-00015. They each cover a three-period glyburide dosing regimen in which delivery per unit of time steps down from the first dose to the second dose and from the second dose to the third dose.

Three-dose step-down administration for clinically-effective glyburide level

Administering a glyburide drug to a patient in a manner to achieve a clinically-effective level, comprising a first dose during a first period of time, a second dose during a second period of time, and a third dose during a third period of time, wherein the second dose delivers less glyburide per unit of time than the first dose and the third dose delivers less glyburide per unit of time than the second dose.

Three-dose step-down administration to achieve substantially steady-state level

Administering a glyburide drug to a patient in a manner to achieve a substantially steady-state level, comprising a first dose during a first period of time, a second dose during a second period of time, and a third dose during a third period of time, wherein the second dose delivers less glyburide per unit of time than the first dose and the third dose delivers less glyburide per unit of time than the second dose.

Both independent claims focus on a three-time-period glyburide administration regimen with a decreasing per-unit-time delivery rate from the first dose to the second dose and from the second dose to the third dose, with one independent claim framed around achieving a clinically-effective level and another framed around achieving a substantially steady-state level.

Stated Advantages

Rapidly achieve and maintain therapeutic glyburide plasma levels.

Avoid excessive exposure and hypoglycemia.

Attain steady state concentration after bolus plus continuous infusion.

Documented Applications

Treating sulfonylurea-responsive acute conditions selected from acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, and hypoxia/ischemia.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.